Helius Medical Technologies, Inc. (OTCMKTS:HSDT) Director Dane Andreeff acquired 167,000 shares of the company’s stock in a transaction on Monday, November 13th. The shares were purchased at an average cost of $2.58 per share, with a total value of $430,860.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Helius Medical Technologies, Inc. (OTCMKTS:HSDT) opened at $2.16 on Wednesday. Helius Medical Technologies, Inc. has a twelve month low of $1.29 and a twelve month high of $4.14.
Helius Medical Technologies Company Profile
Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device.
Receive News & Ratings for Helius Medical Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.